What is Alamar Biosciences 's D&A?

Alamar Biosciences (ALMR) reported D&A of $1.17M in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Alamar Biosciences ALMR D&A

D&A at other companies

KKR Real Estate Finance TrustKREF

$979K+99.8%

Revolution Medicines, Inc.RVMD

$2.35M+38.7%

ROP

Roper Technologies, Inc.ROP

$10M+9.9%

AutoNationAN

$63M+1.9%

Huntington BancsharesHBAN

$191M-8.6%

AccentureACN

$1.65M-68.4%

Other financials

Income statement

See full

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

See full

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

See full

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

See full

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

See full

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alamar Biosciences 's D&A?: Alamar Biosciences (ALMR) reported D&A of $1.17M in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.